Catalio Capital Management, LP is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $2.2 billion in regulatory assets under management. Its private funds, of all types, hold $1.4 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +18.2% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +64.1% from Q1 2025 to Q2 2026, compared with +27.4% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $2.2 billionForm ADV Item 5.F
- Gross assets of private funds
- $1.4 billionAll private fund types, Form ADV
- Hedge funds managed
- 123 private funds in total
- Employees
- 30Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 310374
- Latest Form ADV
- 03/31/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +22.9% | +14.8% |
| Q1 2026 | -3.8% | -4.6% |
| Q4 2025 | +25.6% | +2.4% |
| Q3 2025 | +16.7% | +7.8% |
| Q2 2025 | +2.7% | +10.4% |
| Q1 2025 | -7.7% | -4.5% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 47 share positions ($538,308,196) reported by Catalio Capital Management, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Avalyn Pharmaceuticals Inc8.99%
- Bristol-myers Squibb Co5.79%
- Bridgebio Pharma Inc5.20%
- Parabilis Medicines Inc4.94%
- Johnson & Johnson4.89%
- Ascendis Pharma A/s4.29%
- Arrowhead Pharmaceuticals In3.83%
- Syndax Pharmaceuticals Inc3.57%
- Definium Therapeutics Inc3.52%
- Celcuity Inc3.41%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Avalyn Pharmaceuticals Inc | $48,400,265 | 8.99% | 1,698,851 | +1.37% |
| Bristol-myers Squibb Co | $31,182,278 | 5.79% | 499,716 | +21.01% |
| Bridgebio Pharma Inc | $27,972,304 | 5.20% | 425,111 | -6.58% |
| Parabilis Medicines Inc | $26,608,348 | 4.94% | 824,043 | Unchanged |
| Johnson & Johnson | $26,340,571 | 4.89% | 99,496 | -28.39% |
| Ascendis Pharma A/s | $23,112,214 | 4.29% | 101,445 | +219.42% |
| Arrowhead Pharmaceuticals In | $20,632,916 | 3.83% | 315,247 | New |
| Syndax Pharmaceuticals Inc | $19,241,988 | 3.57% | 1,023,510 | -15.81% |
| Definium Therapeutics Inc | $18,952,510 | 3.52% | 497,964 | -11.50% |
| Celcuity Inc | $18,338,028 | 3.41% | 230,609 | New |
| Septerna Inc | $17,765,607 | 3.30% | 454,015 | -15.32% |
| Guardant Health Inc | $16,512,390 | 3.07% | 92,579 | New |
| Protagonist Therapeutics Inc | $15,838,572 | 2.94% | 112,418 | +5.26% |
| 10X Genomics Inc | $14,821,660 | 2.75% | 164,029 | New |
| Amylyx Pharmaceuticals Inc | $14,721,166 | 2.73% | 505,882 | New |
| Mineralys Therapeutics Inc | $14,659,937 | 2.72% | 583,364 | -10.07% |
| Edwards Lifesciences Corp | $13,907,965 | 2.58% | 161,121 | +29.13% |
| Corvus Pharmaceuticals Inc | $11,767,668 | 2.19% | 1,021,499 | -5.49% |
| Veradermics Inc | $11,595,165 | 2.15% | 95,646 | +108.58% |
| Entera Bio LTD | $11,411,763 | 2.12% | 3,921,568 | New |
| Disc Medicine Inc | $11,305,531 | 2.10% | 172,709 | +8.36% |
| Odyssey Therapeutics Inc | $10,173,183 | 1.89% | 457,839 | Unchanged |
| 4D Molecular Therapeutics In | $9,798,815 | 1.82% | 684,753 | +45.30% |
| Ultragenyx Pharmaceutical In | $9,044,453 | 1.68% | 601,760 | -4.86% |
| Biomarin Pharmaceutical Inc | $8,698,260 | 1.62% | 144,971 | New |
| Annexon Inc | $8,404,189 | 1.56% | 1,986,806 | New |
| Rhythm Pharmaceuticals Inc | $8,151,737 | 1.51% | 85,614 | New |
| Structure Therapeutics Inc | $8,133,608 | 1.51% | 260,109 | -5.95% |
| Nektar Therapeutics | $7,678,135 | 1.43% | 126,817 | New |
| Immunocore Hldgs PLC | $6,421,026 | 1.19% | 211,985 | +43.19% |
| Cogent Biosciences Inc | $5,370,266 | 1.00% | 167,716 | New |
| Kailera Therapeutics Inc | $5,353,125 | 0.99% | 468,750 | Unchanged |
| Natera Inc | $5,178,774 | 0.96% | 12,530 | -84.75% |
| Fractyl Health Inc | $4,813,425 | 0.89% | 8,841,707 | +43.33% |
| Kardigan Inc | $4,609,375 | 0.86% | 312,500 | Unchanged |
| Eledon Pharmaceuticals Inc | $4,141,898 | 0.77% | 1,637,114 | -3.42% |
| Heartflow Inc | $3,729,708 | 0.69% | 74,969 | -87.14% |
| Bridgebio Oncology Therapeut | $2,868,081 | 0.53% | 699,532 | +9.85% |
| Korsana Biosciences Inc | $2,806,464 | 0.52% | 87,702 | New |
| Freenome Inc | $2,491,178 | 0.46% | 158,170 | New |
| Protara Therapeutics Inc | $1,562,475 | 0.29% | 512,287 | -1.51% |
| Karyopharm Therapeutics Inc | $1,190,953 | 0.22% | 976,191 | +3.76% |
| Hyperfine Inc | $1,052,949 | 0.20% | 1,303,155 | -1.28% |
| Metagenomi Therapeutics Inc | $560,733 | 0.10% | 528,993 | Unchanged |
| Faeth Therapeutics Inc | $437,713 | 0.08% | 14,718 | Unchanged |
| Outset Med Inc | $322,368 | 0.06% | 107,456 | -9.15% |
| Adarx Pharmaceuticals Inc | $226,459 | 0.04% | 11,357 | New |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 14 new positions, 6 sold out, 12 increased, 15 reduced and 6 unchanged.
Number of positions (a count, not dollars)
- New positions14
- Increased12
- Unchanged6
- Reduced15
- Sold out6
New positions
| Stock | Value | Shares |
|---|---|---|
| Arrowhead Pharmaceuticals In | $20,632,916 | 315,247 |
| Celcuity Inc | $18,338,028 | 230,609 |
| Guardant Health Inc | $16,512,390 | 92,579 |
| 10X Genomics Inc | $14,821,660 | 164,029 |
| Amylyx Pharmaceuticals Inc | $14,721,166 | 505,882 |
| Entera Bio LTD | $11,411,763 | 3,921,568 |
| Biomarin Pharmaceutical Inc | $8,698,260 | 144,971 |
| Annexon Inc | $8,404,189 | 1,986,806 |
| Rhythm Pharmaceuticals Inc | $8,151,737 | 85,614 |
| Nektar Therapeutics | $7,678,135 | 126,817 |
| Cogent Biosciences Inc | $5,370,266 | 167,716 |
| Korsana Biosciences Inc | $2,806,464 | 87,702 |
| Freenome Inc | $2,491,178 | 158,170 |
| Adarx Pharmaceuticals Inc | $226,459 | 11,357 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Gilead Sciences Inc | $34,024,499 | 269,309 |
| Incyte Corp | $21,722,837 | 191,627 |
| Axsome Therapeutics Inc. | $10,569,658 | 43,182 |
| Dyne Therapeutics Inc | $5,439,873 | 244,929 |
| Dianthus Therapeutics Inc | $3,211,089 | 32,941 |
| Ataibeckley Inc | $1,037,442 | 196,858 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Ascendis Pharma A/s | +69,686 | +219.42% | $23,112,214 | 101,445 |
| Veradermics Inc | +49,790 | +108.58% | $11,595,165 | 95,646 |
| Bristol-myers Squibb Co | +86,755 | +21.01% | $31,182,278 | 499,716 |
| Edwards Lifesciences Corp | +36,343 | +29.13% | $13,907,965 | 161,121 |
| 4D Molecular Therapeutics In | +213,499 | +45.30% | $9,798,815 | 684,753 |
| Immunocore Hldgs PLC | +63,940 | +43.19% | $6,421,026 | 211,985 |
| Fractyl Health Inc | +2,672,958 | +43.33% | $4,813,425 | 8,841,707 |
| Disc Medicine Inc | +13,325 | +8.36% | $11,305,531 | 172,709 |
| Protagonist Therapeutics Inc | +5,619 | +5.26% | $15,838,572 | 112,418 |
| Avalyn Pharmaceuticals Inc | +23,021 | +1.37% | $48,400,265 | 1,698,851 |
| Bridgebio Oncology Therapeut | +62,718 | +9.85% | $2,868,081 | 699,532 |
| Karyopharm Therapeutics Inc | +35,336 | +3.76% | $1,190,953 | 976,191 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Natera Inc | -69,651 | -84.75% | $5,178,774 | 12,530 |
| Heartflow Inc | -508,086 | -87.14% | $3,729,708 | 74,969 |
| Johnson & Johnson | -39,450 | -28.39% | $26,340,571 | 99,496 |
| Syndax Pharmaceuticals Inc | -192,188 | -15.81% | $19,241,988 | 1,023,510 |
| Septerna Inc | -82,137 | -15.32% | $17,765,607 | 454,015 |
| Definium Therapeutics Inc | -64,708 | -11.50% | $18,952,510 | 497,964 |
| Bridgebio Pharma Inc | -29,930 | -6.58% | $27,972,304 | 425,111 |
| Mineralys Therapeutics Inc | -65,358 | -10.07% | $14,659,937 | 583,364 |
| Corvus Pharmaceuticals Inc | -59,389 | -5.49% | $11,767,668 | 1,021,499 |
| Structure Therapeutics Inc | -16,441 | -5.95% | $8,133,608 | 260,109 |
| Ultragenyx Pharmaceutical In | -30,744 | -4.86% | $9,044,453 | 601,760 |
| Eledon Pharmaceuticals Inc | -57,957 | -3.42% | $4,141,898 | 1,637,114 |
| Outset Med Inc | -10,823 | -9.15% | $322,368 | 107,456 |
| Protara Therapeutics Inc | -7,861 | -1.51% | $1,562,475 | 512,287 |
| Hyperfine Inc | -16,886 | -1.28% | $1,052,949 | 1,303,155 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Fractyl Health, Inc. | 13G | 5.6% | 736,807 | Oct 13, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 13, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private equity funds filing Form D (1)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (15)
As reported in the adviser's Form ADV filed Mar 26, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures